Roche Diagnostics plans to invest up to $550 million in its Indianapolis site by 2030 to expand manufacturing capabilities for continuous glucose monitoring (CGM) systems, the company announced Monday.

The Indianapolis facility, which serves as the North American headquarters for the Switzerland-based diagnostics and pharmaceutical firm, will become a key production hub for Roche’s CGM technology. The expansion is expected to create several hundred permanent manufacturing jobs along with thousands of temporary construction roles.

Brad Moore, president and CEO of Roche Diagnostics North America, said the investment reflects the company’s focus on improving diabetes care through increased access to monitoring technologies. “By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide,” he said in a statement.
Roche cited the growing prevalence of diabetes — affecting more than 38 million Americans — as a driving factor in the expansion. The new facility is intended to support broader domestic production and reduce reliance on overseas supply chains, in line with national strategies to bolster local manufacturing.

The Indianapolis campus already includes research and development labs, manufacturing, distribution, IT, and administrative operations. It produces about 5.2 billion Accu-Chek test strips annually and supports distribution to over 50 countries.

This initiative adds to more than $800 million Roche has invested in its U.S. operations since 2015. Company officials described the move as part of a long-term strategy to strengthen its presence in the U.S. market and expand access to diagnostics solutions.

Roche is headquartered in Basel, Switzerland, and operates globally as one of the largest biotech companies, with business segments spanning pharmaceuticals and in vitro diagnostics.

U.S. Healthcare Homepage